Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,59 MB, PDF-dokument

The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors ≤ 10 mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and meta-analysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6927). Median follow-up was 36–123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p < 0.0001) and OS (HR 0.17, p = 0.011) were found for patients receiving trastuzumab and chemotherapy compared to no trastuzumab/chemotherapy based on four and two studies. The prognosis was good even for patients without trastuzumab treatment: 5-year DFS 88.3% and 5-year OS 95.9%.
OriginalsprogEngelsk
Artikelnummer103952
TidsskriftCritical Reviews in Oncology/Hematology
Vol/bind184
Antal sider11
ISSN1040-8428
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This study is part of a PhD-project supported by the Danish Cancer Society, Denmark (R246-A14574-19-S73); Interne Forskningsmidler, Herlev and Gentofte Hospital, Denmark; Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat, Denmark (20006–1846); Dansk Kræftforskningsfond, Denmark; Region Sjællands Sundhedsvidenskabelige Forskningsfond, Denmark (R19A283B198); Dansk Brystkirurgisk Selskabs legat, Denmark; Helsefonden, Denmark (20-B-0003). The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Funding Information:
This study is part of a PhD-project supported by the Danish Cancer Society , Denmark ( R246-A14574-19-S73 ); Interne Forskningsmidler, Herlev and Gentofte Hospital , Denmark; Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat , Denmark ( 20006–1846 ); Dansk Kræftforskningsfond , Denmark; Region Sjællands Sundhedsvidenskabelige Forskningsfond , Denmark ( R19A283B198 ); Dansk Brystkirurgisk Selskabs legat , Denmark; Helsefonden , Denmark ( 20-B-0003 ). The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Publisher Copyright:
© 2023 The Authors

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 363664920